News & Updates

Powder for oral suspension 250 mg/5 mL x 70 mL

Empirical antibiotic therapy is critical in managing serious infections when the causative pathogen is still unknown. Among broad-spectrum options, piperacillin–tazobactam remains a cornerstone due to its wide antimicrobial coverage and strong clinical outcomes.

Protecting infants against RSV begins before birth. At a Pfizer-sponsored symposium during ESCMID Global 2026, experts reviewed the latest evidence on maternal RSV immunization, including disease burden, effectiveness, safety, and implementation. Presentations by Professors Marta Nunes, Paolo Manzoni, and Dr Olivia Anselem highlighted how maternal vaccination protects against severe RSV disease in early infancy. Professor Beate Kampmann chaired the session.

In conjunction with World Immunisation Week, observed in the last week of April, Pfizer, together with healthcare professionals, launched “For the Reasons that Matter”, a regional public awareness campaign to raise awareness of adult respiratory health across Malaysia, Indonesia, Singapore, and the Philippines. 

[ Booster Workshop 1 ] 

[ LGU vaccination 1 ]

Respiratory syncytial virus (RSV) remains a leading cause of hospitalisation and severe lower respiratory tract infection (LRTI) in infants worldwide. [Lancet 2022;399:2047-2064; Lancet 2017;390:946-958] In recent years, two immunoprophylactic strategies have become available to protect infants, namely maternal immunisation with the RSV prefusion F (RSVpreF) vaccine and passive immunisation of infants with the long-acting monoclonal antibody nirsevimab.

Outpatient use of nirmatrelvir/ritonavir lowers the risk of severe COVID-19-related outcomes, regardless of age or vaccination status, in a large, nationally representative cohort study in Taiwan, highlighting the importance of early antiviral treatment in ageing and unvaccinated populations.

Prescribing patterns for nirmatrelvir/ritonavir within a healthcare system in Eastern Massachusetts, US, reveal significant demographic and socioeconomic differences, according to a retrospective study.

A study presented at IDWeek 2025 demonstrates substantial medication cost savings, shorter hospital stays, reduced treatment duration, and lower rates of progression to severe disease when nirmatrelvir-ritonavir (NMV/r) was added to the acute care formulary for treating elderly patients with mild-to-moderate COVID-19.